OBJECTIVE  To comprehensively assess the rationality and safety of clinical application of ceftazidime-avibactam (CAZ/AVI) so as to provide bases for reasonable and safe application of the drugs.

METHODS  A total of 137 patients who were hospitalized in Tianjin First Central Hospital and were treated with CAZ/AVI from Jan. 2023 to Jan. 2024 were recruited as the research subjects. The relevant informations involving the baseline data, infection sites, etiological tests, status of drug utilization and adverse reactions were investigated and statically analyzed. The rating form was designed based on relevant guideline consensus and package insert, and the rationality and safety of clinical application of days were evaluated.

RESULTS  Totally 137 valid cases were enrolled in the study, 88 (64.23%) of whom were male, and 49 (35.77%) were female, with the mean age (52±21.89) years old and the average medication duration (12.2±6.45)days. Totally 79 case-times of drug administration were unreasonable, involving 75 patients; unsuited indications, unreasonable treatment course, absence of special consultation and ward round records and no curative effect evaluation after drug administration for 48-72 hours were the major manifestations. The total effective rate of CAZ/AVI treatment was 87.62%, 5 patients had CAZ/AVI-associated adverse reactions, with the incidence of adverse reactions 3.65%.

CONCLUSION  It is necessary for the hospital to further standardize and optimize the clinical utilization of CAZ/AVI, strictly conform to the medication indications, and strengthen the medication surveillance so as to raise the rationality and safety of medication.